Clinical efficacy and safety of intravitreal injection Ranibizumab assisted 25G+ minimally invasive VRS in the treatment of severe PDR

AIM:To study the efficacy and safety of intravitreal injection ranibizumab(IVR)assisted 25G+ minimally invasive vitreoretinal surgery(VRS)in the treatment of severe proliferative diabetic retinopathy(PDR). <p>METHODS: Totally 61 patients and 74 eyes were selected with severe PDR from March 201...

Full description

Bibliographic Details
Main Author: Hui Ren
Format: Article
Language:English
Published: Press of International Journal of Ophthalmology (IJO PRESS) 2017-08-01
Series:Guoji Yanke Zazhi
Subjects:
Online Access:http://ies.ijo.cn/cn_publish/2017/8/201708027.pdf
id doaj-66488a313a9d4b09b7ed6dd809d90895
record_format Article
spelling doaj-66488a313a9d4b09b7ed6dd809d908952020-11-24T23:47:17ZengPress of International Journal of Ophthalmology (IJO PRESS)Guoji Yanke Zazhi1672-51231672-51232017-08-011781508151110.3980/j.issn.1672-5123.2017.8.27Clinical efficacy and safety of intravitreal injection Ranibizumab assisted 25G+ minimally invasive VRS in the treatment of severe PDRHui Ren0Aier Eye Hospital(Chengdu), Chengdu 610041, Sichuan Province, ChinaAIM:To study the efficacy and safety of intravitreal injection ranibizumab(IVR)assisted 25G+ minimally invasive vitreoretinal surgery(VRS)in the treatment of severe proliferative diabetic retinopathy(PDR). <p>METHODS: Totally 61 patients and 74 eyes were selected with severe PDR from March 2015 to June 2016 in our hospital. According to the principle of voluntary, 37 eyes of 31 cases in the VRS before the IVR treatment was set to the joint group, 37 eyes of 30 cases line pure VRS was set to the VRS group. We compared the vitreous volume, logMAR, mean IOP, macular central retinal thickness and complications between the 2 groups. <p>RESULTS: The blood rate of glass in the combination group was 8% after 1wk of postoperative which was significantly lower than that of the VRS group 27%(<i>χ<sup>2</sup></i>=4.573, <i>P</i>=0.032). The glass volume blood rate of the combined group was 0 after 1mo of postoperative while the VRS was 16%(<i>P</i>=0.033). The blood rate of glass in the combination group was 0 at 3mo of postoperative, and 8% in the VRS group(<i>P</i>=0.238). The LogMAR in the combined group was significantly lower than that in the VRS group(<i>t</i>=2.320, <i>P</i>=0.023). There was no significant difference in the mean IOP between the two groups(<i>t</i>=0.516, <i>P</i>=0.608). The mean macular retinal thickness of the combined group was 298.8±78.3μm which significantly lower than the VRS group 357.1±86.2μm(<i>t</i>=3.045, <i>P</i>=0.003). The combined high intraocular pressure rate of the combined group was 14% which was significantly lower than 32% of the control group(<i>χ<sup>2</sup></i>=10.385, <i>P</i>=0.001). The rate of anterior membrane of the retina of the combined group, the rate of recurrent traction and the rate of retinal detachment of the newborn were lower than that of the VRS group, but the difference was not statistically significant(<i>P</i>>0.05). <p>CONCLUSION: IVR assisted VRS, although there is a certain controversy, but in the appropriate dose, frequency and time to achieve significant efficacy, safety is also high.http://ies.ijo.cn/cn_publish/2017/8/201708027.pdfdiabetic retinopathyvitrectomymonoclonal antibody against vascular endothelial growth factorvitreous hemorrhagemacular thicknessmacular thickness
collection DOAJ
language English
format Article
sources DOAJ
author Hui Ren
spellingShingle Hui Ren
Clinical efficacy and safety of intravitreal injection Ranibizumab assisted 25G+ minimally invasive VRS in the treatment of severe PDR
Guoji Yanke Zazhi
diabetic retinopathy
vitrectomy
monoclonal antibody against vascular endothelial growth factor
vitreous hemorrhage
macular thickness
macular thickness
author_facet Hui Ren
author_sort Hui Ren
title Clinical efficacy and safety of intravitreal injection Ranibizumab assisted 25G+ minimally invasive VRS in the treatment of severe PDR
title_short Clinical efficacy and safety of intravitreal injection Ranibizumab assisted 25G+ minimally invasive VRS in the treatment of severe PDR
title_full Clinical efficacy and safety of intravitreal injection Ranibizumab assisted 25G+ minimally invasive VRS in the treatment of severe PDR
title_fullStr Clinical efficacy and safety of intravitreal injection Ranibizumab assisted 25G+ minimally invasive VRS in the treatment of severe PDR
title_full_unstemmed Clinical efficacy and safety of intravitreal injection Ranibizumab assisted 25G+ minimally invasive VRS in the treatment of severe PDR
title_sort clinical efficacy and safety of intravitreal injection ranibizumab assisted 25g+ minimally invasive vrs in the treatment of severe pdr
publisher Press of International Journal of Ophthalmology (IJO PRESS)
series Guoji Yanke Zazhi
issn 1672-5123
1672-5123
publishDate 2017-08-01
description AIM:To study the efficacy and safety of intravitreal injection ranibizumab(IVR)assisted 25G+ minimally invasive vitreoretinal surgery(VRS)in the treatment of severe proliferative diabetic retinopathy(PDR). <p>METHODS: Totally 61 patients and 74 eyes were selected with severe PDR from March 2015 to June 2016 in our hospital. According to the principle of voluntary, 37 eyes of 31 cases in the VRS before the IVR treatment was set to the joint group, 37 eyes of 30 cases line pure VRS was set to the VRS group. We compared the vitreous volume, logMAR, mean IOP, macular central retinal thickness and complications between the 2 groups. <p>RESULTS: The blood rate of glass in the combination group was 8% after 1wk of postoperative which was significantly lower than that of the VRS group 27%(<i>χ<sup>2</sup></i>=4.573, <i>P</i>=0.032). The glass volume blood rate of the combined group was 0 after 1mo of postoperative while the VRS was 16%(<i>P</i>=0.033). The blood rate of glass in the combination group was 0 at 3mo of postoperative, and 8% in the VRS group(<i>P</i>=0.238). The LogMAR in the combined group was significantly lower than that in the VRS group(<i>t</i>=2.320, <i>P</i>=0.023). There was no significant difference in the mean IOP between the two groups(<i>t</i>=0.516, <i>P</i>=0.608). The mean macular retinal thickness of the combined group was 298.8±78.3μm which significantly lower than the VRS group 357.1±86.2μm(<i>t</i>=3.045, <i>P</i>=0.003). The combined high intraocular pressure rate of the combined group was 14% which was significantly lower than 32% of the control group(<i>χ<sup>2</sup></i>=10.385, <i>P</i>=0.001). The rate of anterior membrane of the retina of the combined group, the rate of recurrent traction and the rate of retinal detachment of the newborn were lower than that of the VRS group, but the difference was not statistically significant(<i>P</i>>0.05). <p>CONCLUSION: IVR assisted VRS, although there is a certain controversy, but in the appropriate dose, frequency and time to achieve significant efficacy, safety is also high.
topic diabetic retinopathy
vitrectomy
monoclonal antibody against vascular endothelial growth factor
vitreous hemorrhage
macular thickness
macular thickness
url http://ies.ijo.cn/cn_publish/2017/8/201708027.pdf
work_keys_str_mv AT huiren clinicalefficacyandsafetyofintravitrealinjectionranibizumabassisted25gminimallyinvasivevrsinthetreatmentofseverepdr
_version_ 1725490562234056704